CN Bio announced a strategic parntership with Pharmaron. Pharmaron will verify CN Bio’s PhysioMimix® technology in existing applications and work on integrating OOC technologies into its R&D platform.
The collaboration will also investigate the creation of new applications to meet unmet needs in drug research and development.
The collaboration’s first phase will focus on validating CN Bio’s PhysioMimix technology for existing applications in disease modeling, toxicity testing, and absorption, distribution, metabolism, and excretion (ADME) research.
Following successful validation, the firms will collaborate to implement the platform in key R&D areas and co-develop unique applications to enhance the capabilities of OOC technologies.
Pharmaron is a global drug R&D service platform that offers end-to-end services for drug discovery, preclinical testing, and clinical development. Through the collaboration, CN Bio will install PhysioMimix instruments at Pharmaron’s laboratories around the world, allowing for the joint development of cutting-edge OOC solutions adapted to evolving R&D difficulties.
Leadership Comments
Dr Paul Brooks, CEO, CN Bio, said: “Pharmaron is a global, premier and trusted service provider for the life sciences industry. As such, Pharmaron were the ideal partner for CN Bio as we look to accelerate the growth of our OOC solutions portfolio in new and existing application areas. By working closely together and leveraging the industry-leading expertise of each company, we can share resources that enable us to progress new, innovative solutions from concept to global market deployment more effectively than ever before.
Dr Tomasz Kostrzewski, CSO, CN Bio, commented: “The developments this partnership will enable are especially important given the recent FDA announcement, outlining their plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant models. Our platform is best placed to serve current market gaps including testing for immune-mediated organ damage. Together we can expedite this key development in line with global momentum for more ethical advancements that reduce costs and improve human health.”
Dr Hua Yang, CSO, Pharmaron, added: “We are committed to continuous innovation that enhances the quality of our services and accelerates drug discovery and development. Organ-on-a-chip technology holds significant potential to advance translational science by improving our understanding of drugability at the preclinical stage. We are pleased to collaborate with CN Bio to explore how this technology can add meaningful value to our partners’ development programs.”
For Further Info, CLICK HERE
